These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34348128)

  • 1. AOP and IATA applied to ocular surface toxicity.
    Bonneau N; Baudouin C; Brignole-Baudouin F
    Regul Toxicol Pharmacol; 2021 Oct; 125():105021. PubMed ID: 34348128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of current alternative models in the context of ocular surface toxicity.
    Bonneau N; Baudouin C; Réaux-Le Goazigo A; Brignole-Baudouin F
    J Appl Toxicol; 2022 May; 42(5):718-737. PubMed ID: 34648674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategy Combining Nonanimal Methods for Ocular Toxicity Evaluation.
    Valadares MC; de Oliveira GAR; de Ávila RI; da Silva ACG
    Methods Mol Biol; 2021; 2240():175-195. PubMed ID: 33423234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated Approaches to Testing and Assessment: OECD Activities on the Development and Use of Adverse Outcome Pathways and Case Studies.
    Sakuratani Y; Horie M; Leinala E
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():20-28. PubMed ID: 29316278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated Approaches to Testing and Assessment.
    Casati S
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():51-55. PubMed ID: 29604238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replacing the refinement for skin sensitization testing: Considerations to the implementation of adverse outcome pathway (AOP)-based defined approaches (DA) in OECD guidelines.
    Kolle SN; Landsiedel R; Natsch A
    Regul Toxicol Pharmacol; 2020 Aug; 115():104713. PubMed ID: 32562760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of mechanistic information organised within the AOP framework to increase regulatory uptake of the developmental neurotoxicity (DNT) in vitro battery of assays.
    Sachana M; Willett C; Pistollato F; Bal-Price A
    Reprod Toxicol; 2021 Aug; 103():159-170. PubMed ID: 34147625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Challenge for Adverse Outcome Pathway (AOP)-based Chemical Safety Assessment].
    Yamada T; Ashikaga T; Kojima H; Hirose A
    Yakugaku Zasshi; 2020; 140(4):481-484. PubMed ID: 32238628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards AOP application--implementation of an integrated approach to testing and assessment (IATA) into a pipeline tool for skin sensitization.
    Patlewicz G; Kuseva C; Kesova A; Popova I; Zhechev T; Pavlov T; Roberts DW; Mekenyan O
    Regul Toxicol Pharmacol; 2014 Aug; 69(3):529-45. PubMed ID: 24928565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancing developmental and reproductive toxicity knowledge: A new AOP stemming from glutathione depletion.
    Myden A; Stalford SA; Fowkes A; White E; Hirose A; Yamada T
    Curr Res Toxicol; 2023; 5():100124. PubMed ID: 37808440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA).
    Tollefsen KE; Scholz S; Cronin MT; Edwards SW; de Knecht J; Crofton K; Garcia-Reyero N; Hartung T; Worth A; Patlewicz G
    Regul Toxicol Pharmacol; 2014 Dec; 70(3):629-40. PubMed ID: 25261300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The adverse outcome pathway for skin sensitisation: Moving closer to replacing animal testing.
    Schultz TW; Dimitrova G; Dimitrov S; Mekenyan OG
    Altern Lab Anim; 2016 Oct; 44(5):453-460. PubMed ID: 27805828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A high-level overview of the OECD AOP Development Programme.
    Chauhan V; Hamada N; Wilkins R; Garnier-Laplace J; Laurier D; Beaton D; Tollefsen KE
    Int J Radiat Biol; 2022; 98(12):1704-1713. PubMed ID: 35938955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a tiered in vitro testing strategy for assessing the ocular and dermal irritation/corrosion potential of pharmaceutical compounds for worker safety.
    Graham JC; Wilt N; Costin GE; Villano C; Bader J; Krawiec L; Sly E; Gould J
    Cutan Ocul Toxicol; 2018 Dec; 37(4):380-390. PubMed ID: 30035615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [International trend regarding immunotoxicity evaluation with New Approach Methods (NAMs)].
    Kojima H; Ashikaga T
    Nihon Yakurigaku Zasshi; 2022; 157(5):340-344. PubMed ID: 36047149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Isolated Chicken Eye test to replace the Draize test in rabbits.
    Prinsen MK; Hendriksen CFM; Krul CAM; Woutersen RA
    Regul Toxicol Pharmacol; 2017 Apr; 85():132-149. PubMed ID: 28192172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of peptide reactivity assays for skin sensitisation hazard identification and risk assessment.
    Gerberick GF
    Altern Lab Anim; 2016 Oct; 44(5):437-442. PubMed ID: 27805826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of Computational Methods.
    Patlewicz G; Worth AP; Ball N
    Adv Exp Med Biol; 2016; 856():165-187. PubMed ID: 27671722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OECD/EFSA workshop on developmental neurotoxicity (DNT): The use of non-animal test methods for regulatory purposes.
    Fritsche E; Crofton KM; Hernandez AF; Hougaard Bennekou S; Leist M; Bal-Price A; Reaves E; Wilks MF; Terron A; Solecki R; Sachana M; Gourmelon A
    ALTEX; 2017; 34(2):311-315. PubMed ID: 28407175
    [No Abstract]   [Full Text] [Related]  

  • 20. Expansion of the applicability domain for highly volatile substances on the Short Time Exposure test method and the predictive performance in assessing eye irritation potential.
    Abo T; Yuki T; Xu R; Araki D; Takahashi Y; Sakaguchi H; Itagaki H
    J Toxicol Sci; 2018; 43(7):407-422. PubMed ID: 29973473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.